Answers are grounded in this paper and cite their sources.
OBJECTIVE: Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by multi-organ involvement and a substantial burden of morbidity and mortality. Following the recent national adoption of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) SSc patient pathways by the Flemish Network on Rare Connective Tissue Diseases, this statement aims to provide a comprehensive overview of the clinical and therapeutic management of systemic sclerosis-associated interstitial lung disease (SSc-ILD) within the Belgian healthcare setting. METHODS: A multidisciplinary panel of Belgian experts in interstitial lung disease and systemic sclerosis, together with patient representatives, reviewed current evidence and international recommendations. The panel developed consensus-based guidance adapted to the Belgian context, taking into account clinical practice, healthcare organization and treatment accessibility. RESULTS: The expert panel consolidated key recommendations for the diagnosis, monitoring, multidisciplinary management and treatment of SSc-ILD. Particular emphasis was placed on addressing the complexities of disease management and the high morbidity and mortality associated with SSc-ILD, while ensuring applicability within the Belgian healthcare system. CONCLUSION: Despite the availability of international guidelines for SSc-ILD, differences in therapeutic access, reimbursement policies and the organization of multidisciplinary care necessitate country-specific guidance. This Belgian expert statement aims to support harmonized, equitable and timely access to optimal care for patients with SSc-ILD.
No takes yet. Share an insight, caveat, or question.
Guiot et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: